

- Characterisation of true relapse rates in different geographic areas in the age group mainly affected.
- Assessment of efficacy and safety of short course, high dose primaquine treatment regimens.
- Development of robust point-of-care G6PD diagnostics.
- Investigation of the safety and efficacy of tafenoquine, a long acting 8 aminoquinoline.
- Defining the pharmacokinetic profile of primaquine in at risk populations.
- Confirmation of primaquine efficacy when combined with different blood schizontocidal partner drugs.
- Confirmation of effectiveness of primaquine regimens in clinical practice.
- Quantification of risk of clinically significant haemolysis according to primaquine dose and host susceptibility.
- Development of techniques to distinguish between relapse, reinfection and recrudescence infections.